Human adaptive immune receptors recognizing inactivated poliovirus type 3 capsid antigens

Human adaptive immune receptors recognizing inactivated poliovirus type 3 (IPV3) capsid antigens comprise the repertoire of B-cell receptors (BCRs) and T-cell receptors (TCRs) that specifically identify the structural proteins of the Poliovirus Type 3 Saukett strain (Hogle, 2002). These receptors are the primary mediators of the protective immune response elicited by the inactivated poliovirus vaccine (IPV). BCRs, which are later secreted as antibodies, primarily target the 'D-antigen' sites on the viral capsid proteins VP1, VP2, and VP3 to neutralize the virus and prevent its entry into host cells (Minor, 1992). TCRs recognize proteolytic fragments of these capsid proteins presented by Major Histocompatibility Complex (MHC) molecules, facilitating the activation of helper T-cells and the establishment of long-term immunological memory (WHO, 2022). In the context of public health, these receptors are critical for maintaining population immunity against poliomyelitis, a debilitating disease caused by poliovirus infection (CDC, 2023). Therapeutic strategies involving these receptors focus on vaccine design to optimize their activation and the development of monoclonal antibodies for passive immunization in immunocompromised individuals.

Other names

Poliovirus type 3 specific B-cell receptorsPoliovirus type 3 specific T-cell receptorsAnti-poliovirus type 3 antibodiesIPV3-specific BCRsIPV3-specific TCRsSaukett-specific immune receptors

The inactivated poliovirus type 3 antigens interact with B-cell receptors to stimulate the production of neutralizing antibodies and with T-cell receptors via MHC-presented peptides to induce cellular immunity and memory (WHO, 2022; CDC, 2023).